サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363093

制酸剤の市場規模、シェア、動向分析レポート：タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年

Antacids Market Size, Share & Trends Analysis Report By Type (Tablet, Liquid), By End-use (Retail Pharmacy, Hospital Pharmacy), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 90 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
制酸剤の市場規模、シェア、動向分析レポート：タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月20日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

制酸剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の制酸剤市場規模は2030年までに87億9,000万米ドルに達し、予測期間中のCAGRは3.7％で成長すると予測されています。

時折起こる胸焼けのセルフメディケーションの動向は、市場を牽引する主な要因の一つです。

高齢者人口の増加は制酸剤市場全体にプラスの影響を与えると予想されます。国連経済社会局（DESA）によると、2017年の世界の高齢者人口（60歳以上）は約9億6,200万人でした。この数は、60歳以上の人口が71％増加したラテンアメリカで最も速いペースで増加すると予想され、次いでアジアが66％、アフリカが64％、北米が41％、欧州が23％となっています。

制酸剤市場を運営する主要企業は、チュアブル錠、粉末、ゼリーなどの剤形変更など、患者の要望に応えるための製品改良に注力しています。また、これらのプレーヤーは市場でのプレゼンスを拡大するために提携や買収に関与しています。例えば、2017年にファイザー社はアストラゼネカ社と戦略的契約を締結し、制酸剤ブランドの1つであるNeksiumをインドで75カロールインドルピーで買収し、製品ポートフォリオを強化しました。

制酸剤は店頭で簡単に入手できるため、市場全体の売上に成長機会がもたらされます。主な参入企業は、グラクソ・スミスクライン、アストラゼネカ、ファイザー、サン・ファーマシューティカルズ・インダストリーズ、ドクター・レディーズ・ラボラトリーズ、バイエル、武田薬品工業などです。

制酸剤市場レポートハイライト

  • 2022年、錠剤は他の剤形と比べて高い有効性により制酸剤市場を牽引。液剤は嗜好性が高く、小児や高齢者に好まれるため、急成長が見込まれます。
  • 小売薬局はその入手しやすさと可用性から流通チャネルをリードしています。オンライン薬局は、Pharma 3.0の普及と消費者の意識の高まりにより、最も急成長する分野と予想されます。
  • アジア太平洋地域は、グラクソ・スミスクライン社、ファイザー社、アボット社などの主要プレイヤーの存在により、予測期間中に最も急成長する地域と推定・予測されています。
  • 北米は、様々な消化器疾患の有病率の増加により、2022年に最大の市場シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 制酸剤市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 制酸剤市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 制酸剤市場： タイプの推定・動向分析

  • 制酸剤市場：重要なポイント
  • 制酸剤市場：動向と市場シェア分析、2022年と2030年
  • 錠剤
  • 液体
  • その他

第5章 制酸剤市場： 最終使用推定・動向分析

  • 制酸剤市場：重要なポイント
  • 制酸剤市場：動向と市場シェア分析、2022年と2030年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第6章 制酸剤市場：地域推定・動向分析

  • 地域別の展望
  • 地域別の制酸剤市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • GlaxoSmithKline plc.
    • Bayer AG
    • Pfizer, Inc.
    • Boehringer Ingelheim International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Reckitt Benckiser Group plc.
    • Sanofi
    • Sun Pharmaceuticals Ltd.
    • Takeda Pharmaceutical Company Limited
    • Procter & Gamble
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 3 North America antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 4 North America antacids market, by region, 2018 - 2030 (USD Billion)
  • Table 5 U.S. antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 6 U.S. antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 7 Canada antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 8 Canada antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 9 Europe antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 10 Europe antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 11 Europe antacids market, by region, 2018 - 2030 (USD Billion)
  • Table 12 Germany antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 13 Germany antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 14 UK antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 15 UK antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 16 France antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 17 France antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 18 Italy antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 19 Italy antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 20 Spain antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 21 Spain antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 22 Sweden antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 23 Sweden antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 24 Norway antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 25 Norway antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 26 Denmark antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 27 Denmark antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 28 Asia Pacific antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 29 Asia Pacific antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific antacids market, by region, 2018 - 2030 (USD Billion)
  • Table 31 China antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 32 China antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 33 Japan antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 34 Japan antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 35 India antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 36 India antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 37 Australia antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Australia antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 39 Thailand antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 40 Thailand antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 41 South Korea antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 42 South Korea antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 43 Latin America antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 44 Latin America antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 45 Latin America antacids market, by region, 2018 - 2030 (USD Billion)
  • Table 46 Brazil antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 47 Brazil antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 48 Mexico antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 49 Mexico antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 50 Mexico antacids market, by application, 2018 - 2030 (USD Billion)
  • Table 51 Argentina antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 52 Argentina antacids market, by application, 2018 - 2030 (USD Billion)
  • Table 53 Middle East and Africa antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Middle East and Africa antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 55 Middle East and Africa antacids market, by region, 2018 - 2030 (USD Billion)
  • Table 56 South Africa antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 57 South Africa antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 58 Saudi Arabia antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 59 Saudi Arabia antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 60 Saudi Arabia antacids market, by application, 2018 - 2030 (USD Billion)
  • Table 61 UAE antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 62 UAE antacids market, by end-use, 2018 - 2030 (USD Billion)
  • Table 63 Kuwait antacids market, by type, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait antacids market, by end-use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approach
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Antacids: Market outlook
  • Fig. 9 Antacids: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Antacids market driver impact
  • Fig. 15 Antacids market restraint impact
  • Fig. 16 Antacids market strategic initiatives analysis
  • Fig. 17 Antacids market: Type movement analysis
  • Fig. 18 Antacids market: Type outlook and key takeaways
  • Fig. 19 Tablet market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Liquid market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Antacids market: End-use class movement analysis
  • Fig. 23 Antacids market: End-use outlook and key takeaways
  • Fig. 24 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Global antacids market: Regional movement analysis
  • Fig. 29 Global antacids market: Regional outlook and key takeaways
  • Fig. 30 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Europe. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-693-6

Antacids Market Growth & Trends:

The global antacids market size is expected to reach USD 8.79 billion by 2030, registering a CAGR of 3.7% during the forecast period, according to a new report by Grand View Research, Inc. The trend of self-medication for occasional heartburn is one of the major factors driving the market.

Growing geriatric population is expected to positively impact the overall market for antacid. According to the United Nations Department of Economic And Social Affairs (DESA), the global elderly population (60 years and above), was around 962 million in 2017. This number is expected to grow at the fastest rate in Latin America with 71% increase in population aged 60 and over, followed by Asia with 66%, Africa with 64%, North America with 41%, and Europe with 23%.

Key players operating in antacid market focus on product enhancement to cater to patient requirements, such as changing the dosage form into chewable tablets, powder, and jelly. Also, these players are involved in collaborations and acquisitions to expand their market presence. For instance, in 2017, Pfizer, Inc. entered into a strategic agreement with AstraZeneca to acquire one of the antacid brands, Neksium for a value of INR 75 crores in India to boost its product portfolio.

The easy availability of antacids over-the-counter offer growth opportunities for the sales of overall market. Some of the key players areGlaxoSmithKline plc; AstraZeneca; Pfizer, Inc.; Sun Pharmaceuticals Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Bayer AG; Takeda Pharmaceutical Company Limited.

Antacids Market Report Highlights:

  • In 2022, tablet segment led the antacid market due to high efficacy compared to other dosage forms. Liquid is anticipated to be the fastest growing segment due to its palatable taste and preferred choice for children and elderly population
  • Retail pharmacy led the distribution channel segment due its accessibility and availability. Online pharmacy is anticipated to be the fastest growing segment due to growing adoption of Pharma 3.0 and consumer awareness
  • Asia Pacific is estimated to be the fastest growing region over the forecast period due to presence of key players such as GlaxoSmithKline plc; Pfizer Inc.; and Abbott among others
  • North America held the largest market share in 2022 owing to increasing prevalence of different digestive disorders

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. End-use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antacids Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Antacids Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Antacids Market: Type Estimates & Trend Analysis

  • 4.1. Antacids Market: Key Takeaways
  • 4.2. Antacids Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Tablet
    • 4.3.1. Tablet market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Liquid
    • 4.4.1. Liquid market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Antacids Market: End-use Estimates & Trend Analysis

  • 5.1. Antacids Market: Key Takeaways
  • 5.2. Antacids Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospital Pharmacy
    • 5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Retail Pharmacy
    • 5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Online Pharmacy
    • 5.5.1. Online Pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antacids Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Antacids Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. f
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. GlaxoSmithKline plc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Bayer AG
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Pfizer, Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Boehringer Ingelheim International GmbH
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Dr. Reddy's Laboratories Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Reckitt Benckiser Group plc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Sanofi
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Sun Pharmaceuticals Ltd.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Takeda Pharmaceutical Company Limited
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Procter & Gamble
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives